Background - Fibrosis
Fibrosis, or the formation of excess fibrous connective tissue, is a condition that can take place in many organs and tissues. Fibrosis is often triggered by chronic inflammation and chronic injury. Fibrosis is part of the normal healing processes (such as wound healing) but excessive inflammation-driven fibrosis in key organs can lead to serious health conditions.
Fibrosis can occur in major organs including the pancreas, heart, lungs, kidneys, liver, eyes, and in the skin. Some fibrotic diseases, such as cystic fibrosis, are caused by genetic mutations. Other serious manifestations of fibrosis include idiopathic pulmonary fibrosis, kidney and liver fibrosis, which typically have an inflammation-driven origin.
Recent published research suggests that FAK plays a key role in development of fibrotic disorders and is therefore an attractive therapeutic target. Although Amplia's initial clinical development focus is in oncology, a highly-selective oral FAK inhibitor like AMP945 has considerable potential in treating fibrotic diseases and we are actively considering collaborations.